Abstract: Synthetic and semisythetic bodies having a three-dimensional structure, sized and shaped to resemble apoptotic cells and apoptotic bodies, and having phosphatidyl serine (PS) molecules on the surface thereof, are administered to a patient, to alleviate a variety of disorders such as T-cell mediated disorders (autoimmune conditions). The bodies are believed to trigger and apoptosis-like mechanism in the patient.

Abstract: A medical delivery device comprising an elongate body having a plunger slidably and sealingly engaged to form a cavity to receive fluid materials and a first outlet disposed at an end of said body and has a male luer end portion and a valve assembly is disposed within the first outlet. The valve assembly has a valve means movable between an open position and a closed position and biasing means for biasing the valve means to a closed position. Actuating means are disposed within the male luer end portion and coupled to the valve means such that the valve means is movable to an open position when a female luer end portion of a medical accessory is coupled with the male luer end portion. A second outlet is disposed at the same end as the first outlet for controlling the exchange of gases from the environment to said cavity under the action of the plunger.

Abstract: This invention provides a method for prophylaxis or treatment of an acute inflammatory disorder, comprising administering to a patient an effective amount of pharmaceutically acceptable bodies carrying an effective number of phosphate-containing groups presented or presentable on the surface of said bodies, the phosphate-containing groups comprising a plurality of phosphate-glycerol groups or groups convertible to such groups, to inhibit and/or reduce the progression of the acute inflammatory disorder, said bodies being of a size from about 20 nanometers (nm) to 500 micrometers (?m).

Abstract: Treatment and/or prophylaxis of endothelial dysfunction-related disorders in mammalian patients is effected by administering to the patient effective amounts of apoptotic bodies and/or apoptotic cells.

Abstract: A syringe including a releasable lock means for allowing discharge of a treated biological fluid sample to the patient in response to a release signal to the releasable lock means. The release signal is issued following a positive outcome from a verification process dependent upon temporal data from certain events in the collection, treatment and delivery of the biological fluid sample, and identity data of the patient and the second device with the treated biological fluid.

Abstract: An apparatus for conditioning mammalian blood for subsequent use in a medical procedure includes a cabinet having a secure environment and a door providing the only access to the environment. An input system transports a blood charge from a source to the cabinet and a flask is removably contained in the secure environment and coupled to the charge input system to receive the charge. Stressors are coupled to the cabinet and positioned for operation to create a conditioned charge in the flask. An output system is coupled to the flask and includes a receiver for the conditioned charge. The apparatus includes an automated control system operable upon closing the door to lock the door and to then condition the charge, and to then cause the charge to move from the flask to the receiver.

Abstract: Endothelin-related disorders in mammals can be alleviated by administration to such patients of one or more aliquots of mammalian blood subjected to two or more stressors selected from temperature stressors, electromagnetic emissions and oxidative environments.

Abstract: A syringe comprising a chamber and material transfer portion with a cavity in communication with an inlet portion and an outlet portion. The inlet portion includes an inlet valve means for controlling material flow therethrough, and the material transfer portion includes a control valve operable between a first position to control the inflow of material from the inlet portion to the material container portion, and a second position to control the flow of material from the chamber to the outlet portion, and the outlet portion includes a releasable lock means for allowing discharge the material through the outlet portion.

Abstract: An apparatus for conditioning mammalian blood for subsequent use in a medical procedure includes a cabinet having a secure environment and a door providing the only access to the environment. An input system transports a blood charge from a source to the cabinet and a flask is removably contained in the secure environment and coupled to the charge input system to receive the charge. Stressors are coupled to the cabinet and positioned for operation to create a conditioned charge in the flask. An output system is coupled to the flask and includes a receiver for the conditioned charge. The apparatus includes an automated control system operable upon closing the door to lock the door and to then condition the charge, and to then cause the charge to move from the flask to the receiver.

Abstract: Disclosed herein is a valve assembly comprising a male luer end portion and a female luer end portion and a passage for the transfer of fluids extending between the male and female luer end portions, valve means movable between a first position, in which the passage is closed, and a second position, in which the passage is open, biasing means for biasing the valve means toward the first position, and actuating means extending into the male luer end portion and coupled to the valve means to actuate the valve means when a female luer end portion of a medical accessory is engaged with the male luer end portion.

Abstract: An improved method for treating or preventing a pathological condition in a mammalian subject in which modified mammalian blood is administered to the subject. The method comprises administering to the subject from two to four aliquots of modified mammalian blood, with the administration of any pair of consecutive treatments either being on consecutive days or being separated by a rest period of 1 to 21 days. The treatment is useful for treating or preventing a wide range of pathological conditions in which modified mammalian blood is effective, including preconditioning a mammalian subject to better withstand the adverse effects of ischemic stress, atherosclerosis and rheumatoid arthritis.

Abstract: A method of treating congestive heart failure (CHF) in a human patient comprises treating an aliquot of the patents blood ex vivo with at least one stressor selected from the group consisting of a temperature above or below body temperature, an electromagnetic emission and an oxidative environment, followed by administering the aliquot of treated blood to the patient. The treatment can be used on its own or as an adjunctive therapy in combination with conventional CHF treatments.

Abstract: A syringe includes a releasable lock means for allowing discharge of a treated biological fluid sample to the patient in response to a release signal to the releasable lock means. The release signal is issued following a positive outcome from a verification process dependent upon temporal data from certain events in the collection, treatment and delivery of the biological fluid sample, and identity data of the patient and the syringe with the treated biological fluid.

Abstract: A vessel having a chamber for receiving an untreated material sample, a chamber inlet for releasably mounting a first syringe and establish a dedicated first fluid coupling therewith to dispense an untreated material sample to the chamber; a chamber outlet for releasably mounting a second syringe and establish a dedicated second fluid coupling with the chamber outlet to dispense a treated material sample following treatment to the second syringe; a gas inlet port coupled to an inlet conduit for carrying at least one gas into the chamber; a gas outlet port coupled to an outlet conduit for carrying at least one gas from the chamber, and a temperature sensor.

Abstract: A system for the collection, treatment and delivery of an autologous blood sample, comprising a first syringe for drawing an untreated blood sample from a patient, a blood sample treatment chamber having a chamber inlet for receiving untreated blood from the first syringe and chamber outlet for passage of treated blood to a second syringe coupled thereto. The second syringe includes a releasable lock means for allowing discharge of the treated blood to the patient in response to a release signal. The release signal is issued following a positive outcome from a verification process dependent upon temporal data from certain events in the collection, treatment and delivery of the blood sample, and identity data of the patient and the second syringe with the treated blood.

Abstract: Treatment and/or prophylaxis, in mammalian patients, of neurodegenerative and other neurological medical disorders is effected by administering to the patient effective amounts of apoptotic bodies and/or apoptotic cells, preferably those derived from the patient's own white blood cells, e.g. by extracorporeal treatment of the patient's blood cells to induce apoptosis and administration of the apoptotic bodies and/or cells so formed to the patient.

Abstract: An apparatus for conditioning mammalian blood for subsequent use in a medical procedure includes a cabinet having a secure environment and a door providing the only access to the environment. An input system transports a blood charge from a source to the cabinet and a flask is removably contained in the secure environment and coupled to the charge input system to receive the charge. Stressors are coupled to the cabinet and positioned for operation to create a conditioned charge in the flask. An output system is coupled to the flask and includes a receiver for the conditioned charge. The apparatus includes an automated control system operable upon closing the door to lock the door and to then condition the charge, and to then cause the charge to move from the flask to the receiver.

Abstract: There is provided a combination treatment for slowing or arresting the progression and/or effecting the regression of atherosclerotic plaque deposits in a mammalian patient, said combination treatment including the administration to the patient of a cholesterol lowering drug such as a statin, and the administration to the patient of an aliquot of a patient's own blood which has been treated ex vivo with one or more stressors selected from an oxidative environment, thermal stress and UV light.

Abstract: Disclosed are methods for treating and preventing neurological disorders which have a significant inflammatory component. The methods of the present invention involve extracting blood from a patient, subjecting the blood ex vivo to at least one stressor selected from the group consisting of an oxidative environment, thermal stress and UV light, and then re-administering the blood to the patient, thereby reducing inflammation.

Abstract: A multi-port syringe with a fluid chamber in communication with an inlet valve assembly and an outlet valve assembly disposed intermediate the fluid chamber and the inlet valve assembly, the inlet valve assembly has an inlet valve member operable in an open position and a closed position, the inlet valve member being biased in a closed position by a resilient member. The outlet valve assembly has an outlet valve member operable between a closed position and an open position, and the outlet valve member is maintained in a closed position by a sealing member, and includes anchoring member engaging the outlet valve assembly.